Zenith Drugs Ltd
Incorporated in 2000, Zenith Drugs Limited is a pharmaceutical company specializing in manufacturing and trading medicines, including generic drugs.[1]
- Market Cap ₹ 154 Cr.
- Current Price ₹ 90.0
- High / Low ₹ 114 / 52.8
- Stock P/E 14.2
- Book Value ₹ 36.3
- Dividend Yield 0.00 %
- ROCE 41.0 %
- ROE 63.1 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -30.0%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 92 | 114 | 132 | |
| 85 | 104 | 115 | |
| Operating Profit | 7 | 10 | 17 |
| OPM % | 8% | 9% | 13% |
| 1 | 1 | 1 | |
| Interest | 2 | 3 | 3 |
| Depreciation | 1 | 1 | 1 |
| Profit before tax | 4 | 7 | 13 |
| Tax % | 29% | 29% | 28% |
| 3 | 5 | 10 | |
| EPS in Rs | 5.59 | ||
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 111% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 63% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 0 | 0 | 17 |
| Reserves | 12 | 17 | 45 |
| 19 | 26 | 25 | |
| 38 | 55 | 48 | |
| Total Liabilities | 69 | 98 | 135 |
| 10 | 12 | 11 | |
| CWIP | 3 | 0 | 4 |
| Investments | 0 | 0 | 0 |
| 55 | 86 | 120 | |
| Total Assets | 69 | 98 | 135 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 5 | -4 | -13 | |
| -5 | 0 | 26 | |
| 1 | 5 | -4 | |
| Net Cash Flow | 1 | 1 | 9 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 128 | 158 | |
| Inventory Days | 96 | 182 | |
| Days Payable | 274 | 398 | |
| Cash Conversion Cycle | -50 | -57 | |
| Working Capital Days | 53 | 84 | |
| ROCE % | 27% |
Documents
Announcements
-
Price movement
18 July 2024 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written …
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
17 July 2024 - Zenith Drugs Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Quarter Ended 30th June, 2024, F.Y. 2024-25
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
17 July 2024 - Zenith Drugs Limited has informed about Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th Jun 2024
-
Updates
11 June 2024 - Zenith Drugs Limited has informed regarding submission of financial results for the period ended 31-Mar-2024 in Machine Readable Form / Legible copy''.
-
Statement of deviation(s) or variation(s) under Reg. 32
30 May 2024 - Zenith Drugs Limited has informed about statement of deviation(s) or variation(s) under Reg. 32
Annual reports
No data available.
Product Portfolio[1]
ORS Powder;
Liquid Orals;
Ointments;
Liquid Externals;
Capsules